Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880429 | 0.98 | TDP1 (0.59) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30464299 | 0.85 | TDP1 (0.58) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL999160 | 0.85 | TDP1 (0.58) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL1000350 | 0.84 | TDP1 (0.56) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL16621042 | 0.84 | TDP1 (0.56) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9015187 | 0.83 | CYP1A2 (0.53) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2299003 | 0.81 | CYP1A2 (0.52) | MEN1KMT2ACYP1A2KDM4E | |
| Lithium Ion SCHEMBL2224280 | 0.80 | CYP1A2 (0.50) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL9102522 | 0.80 | CYP1A2 (0.68) | TDP1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9945611 | 0.79 | KDM4E (0.51) | TDP1MEN1KMT2ACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| EP-2533782-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011086377-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CACNA1B, CACNB2, CACNA1C | TDP1 4506/4885NPC1 1879/4885RAB9A 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.